Tectonic Therapeutic
Massachusetts, United States · Biotechnology · 45 employees
Tectonic is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-Protein Coupled Receptors. We have developed a proprietary technology platform called GEODe™ to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease, by addressing challenges that have limited the pace of innovation
Funding history
- Funding Round — $185.0M — Feb 2025
- Funding Round — $80.1M — Apr 2021
Recent signals
- Jun 10, 2026: Tectonic Therapeutic Appoints New Directors
- Feb 14, 2025: Raised $185.0M
- Nov 11, 2024: Launched Tectonic Therapeutic Reports Successful Phase 1a Results for TX45, a New Fusion Protein for Heart Disease Treatment.
- Jun 03, 2024: Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
- Apr 15, 2021: Raised $80.1M
See plans & pricing → Track Tectonic Therapeutic’s funding, hiring, and signals — with verified contacts — on Fundz.